On March 24, 2015 Allele Biotechnology & Pharmaceuticals, Inc. announced Ocata Therapeutics, Inc. will license Allele's induced pluripotent stem cell technology for use in its regenerative ophthalmology products.

Jiwu Wang, Ph.D., CEO of Allele commented "It is particularly rewarding to us that Ocata, a company whose understanding of the science and regulatory requirements in this space is unparalleled, has selected the iPSC technology developed at Allele for application in its own pipeline".  

Visit us at www.allelebiotech.com to learn more about our innovative products & services.